Logo
Login

Company Executives

$ Management Team

Mr. Adam Dubow

General Counsel

Chief Compliance Officer and Secretary

Age 58
Compensation $2.386M USD
Sex Male

Mr. Garry Nicholson

Independent Non-Executive Chairman of the Board

Age 70
Compensation $383.4K USD
Sex Male

Dr. Jeremy Bender

President

Chief Executive Officer

Director

Age 53
Compensation $6.561M USD
Sex Male

Ms. Lauren Merendino

Chief Commercial Officer

Age 50
Compensation -
Sex Female

Mr. Charles York

Chief Financial Officer

Chief Operating Officer

Secretary

Age 48
Compensation $3.896M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 11, 2025
Directors
9
serving now
Independent
8 of 8
stated in the proxy; 1 not stated
Average tenure
3.4 years
from year joined
CEO also chairs the board
No
Garry Nicholson
Director Age On board Independent Committees Other public boards 2024 pay Source
Natalie Holles
52 2021
4 years
 Independent
Compensation Committee · Chair
None stated $337,850
Garry Nicholson
Board chair
 70 2022
3 years
 Independent
Nominating and Corporate Governance Committee
TScan Therapeutics $363,475
Scott Garland
56 2021
4 years
 Independent
Audit Committee
ALX Oncology $330,350
William Grossman
55 2024
1 year
 Independent
Compensation Committee
None stated $911,897
John Josey
64 2020
5 years
 Independent
Nominating and Corporate Governance Committee · Chair
Tortugas Neurosciences Not stated
Jeremy Bender
CEO
 53 2020
5 years
 Not stated None stated Mereo BioPharma Group plc Paid as CEO
Habib Dable
55 2024
1 year
 Independent
Nominating and Corporate Governance Committee
Aerovate Therapeutics, PepGen, Blueprint Medicines $910,022
Saira Ramasastry
49 2021
4 years
 Independent
Audit Committee · Chair
Vir Biotechnology Not stated
Michael Gladstone
Not stated Not stated Independent
Audit Committee
None stated $330,350

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 11, 2025 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans